Outcome of Board Meeting

Date: 28th July, 2026 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code : INDOCO Dear Sir/Madam, Subject: Outcome of Board Meeting held on 28th July, 2026 Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 28th July, 2026 has inter-alia considered and approved Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Please find enclosed copies of the following: a. Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. b. Limited Review Report with unmodified opinion issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c. Press Release. The Board Meeting commenced today at 10:45 a.m. and concluded at 11:45 a.m. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Indoco Remedies Limited Ramanathan Hariharan Company Secretary & Head- Legal INDOCO REMEDIES LIMITED Regd. Office: Indoco House, 166, CST Road, Kalina,Santacruz (E), Mumbai 400 098. Tel:+91:22:26541851/55 Fax:+91-22-26520787 Email: compliance officer@indoco.com Website:www.indoco.com CIN:L85190MH1947PLC005913 STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 S.No. [Particulars (Rs. In Lakhs) Quarterended | Quarter ended | Quarterended | Year ended 30.06.2026 31.03.2026 | 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 | Income from Operations (a) Revenue from Operations 40812 42906 38,561 163354 (b) Other Operating Income 85 2,007 870 5,253 Total Income from Operations (Net) (a+b) 40,897 44,913 39,431 1,68,607 32 | TO ot th ae lr I I nn cc oo mm ee (1+2) 41,34 44 47 451 ,, 90 43 85 39,95 85 98 1,712 ,, 59 76 14 4 |Expenses (a) Cost of materials consumed 8,599 9,825 8777 35,323 (b) Purchases of stock-in-trade 3,959 2,908 3,923 14012 (¢) Changeisn inventoof rfiniisehesd goods, 1487 1,058 (583) 720 work-in-progress and stock-in-trade (d) Employee Benefits expense 9,065 10,098 9,850 39363 (e) Research & Development Expense 1,854 1776 2,167 7,954 (1) Other Expenses 11,712 12,945 13,815 55,520 (&) Finance Costs 2,275 2,273 2,361 8,850 (h) Depreciation and Amortization expense 2,805 2,671 2,520 10,690 5 | T Po rt oa fl i tE x / p (e Ln oss se )s Before Exceptional Items and Tax (3-4) 41, (47 15 26 ) 43 2, ,5 35 94 4 4 (2 2, ,8 83 410 ) 1,72 (, 84 63 12 ) 6 | Exceptional Items (¥) 9,734 368 - (286) 87 |P Tr ao xfi Et x pB ee nfo sr ee s Ta -x C u( r5 r+ e6 n) t 9 1, ,3 02 52 6 2,7 26 92 2 (2,8 - 41) (1,1 24 07 2) - Deferred 34 (265) 34 (873) - MAT Credit Adjustments - - - - Total Tax Expenses 1,090 27 34 (581)) 9 |Profit for the period (7-8) 8,232 2,735 (2,807) (566) 10 |Other Comprehensive Income a [i) Items that will notbe reclassified to profit and loss (60) 403 75) 178 i) Income tax on relating to this item 15 (102) 19 (5) b |i) Items that mabye reclassified to proofr ilotss - (335) 129 - Tii o) tI an lc Oo tm he e t ra x C o on m pr rel ea ht ein ng s t io v t eh i Is n i ct oe mm e (i 45) 58 04 ( 43 12) 1E 3 3 11 (Total Comprehensive income for the year (9+10) 8,187 2,785 (2,766) (433) 12 |Paid up Equity Share Capital (Face value Rs. 2/- each) 1846 1846 1,845 1846 11 43 ||O Et ah re nr i nE gq su pi et ry share (of Rs. 2/- each) 1,08,073 (a) Basic-in Rs. 892 296 (3.04) (061) (b) Diluted- in Rs. 892 296 (3.04) (0.61) Notes: 1 |The unaudited Standalone Results for the Quarter ended 30th June, 2026 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026 The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales and Income from Operations Quarterended | Quarter ended | Quarterended | _ Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) India 22,775 19,363 22,255 89,413 Outside India 18,037 23543 16,306 73,941 Total 40,812 42,906 38,561 1,63,354) The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2026. Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed). (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss. By Order of the Board For Indoco Remedies Ltd Place : Mumbai diti Panandikar Date : July 28, 2026 lanaging Director gokhale & sathe (regd.) chartered accountants 304/308/309/311,udyog mandir no.1, 7-c, bhagoji keer marg,mahim, mumbai - 400 016,maharashtra,india. Independent Auditors’ Limited Review Report on quarterly unaudited standalone financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 The Board of Directors, Indoco Remedies Limited 1 We have reviewed the accompanying statement of unaudited standalone financial results (“the Statement”) of Indoco Remedies Limited (‘the Company’) for the quarter ended 30 June 2026 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended. 2 This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. 3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4 Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial ye [Showing first 8,000 characters — download PDF for full document]